Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538064 · ClinicalTrials.gov registry record
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
A clinical trial of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), sponsored by Takeda.
- Recruiting
- Registry status
- 30
- Enrollment target
- 15
- Study locations
NCT06538064: Recruiting study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), sponsored by Takeda.
NCT06538064 is a study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) that is actively recruiting participants, run by Takeda. The registered enrollment target is 30 participants, below the 43-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (30% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06538064, a study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 15
- Study locations
Study Summary
The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are with HyQvia and their previous treatment, how their work productivity and activity is impacted and learn about their CIDP signs and symptoms. Other aims are to collect information on any medical problems or side effects during the treatment with HyQvia, learn how effective treatment of CIDP with HyQvia is and understand details on the use of HyQvia in standard clinical routine as well on the need for healthcare intervention (such as emergency room visits or hospital visits or stays). During the study, data will be collected from medical records already available, interviews with participants at study start and study completion and via questionnaires completed by participants. Participants will be treated as per the doctor's or the clinic's routine.
Primary Outcome
The novel treatment preference questionnaires measure participant's treatment preferences for switching to HyQvia from other subcutaneous immunoglobulin/intravenous immunoglobulin (SCIG/IVIG) treatments for CIDP. It includes overall preference for switching from prior therapy to HyQvia, reason for switching from prior therapy type (like other SCIG, IVIG, corticosteroids, or plasma exchange) to HyQvia for the maintenance treatment of CIDP, current/future preference for HyQvia, reason for HyQvia o
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (15)
Other
- Arhus Universtitetshospital - Aarhus N
- Rigshospitalet - København Ø
- Judisches Krankenhaus Berlin - Berlin
California
- Samir Macwan MD Inc - Rancho Mirage
- Neuro/Psych Sleep Clinic - San Francisco
Florida
- Nova Clinical Research, LLC - Bradenton
- Suncoast Neuroscience Associates, Inc. - St. Petersburg
Connecticut
- Yale School Of Medicine - New Haven
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Illinois
- HSHS St. Elizabeths Hospital - O'Fallon
Kansas
- University of Kansas Medical Center Research Institute, Inc. - Kansas City
North Carolina
- Wake Forest University - School of Medicine - Central - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2027-08-17 |
What NCT06538064 shows while recruiting
NCT06538064 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 43-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06538064 lists 15 locations in 11 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06538064 about?
NCT06538064 is a clinical study titled "A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care". The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are with HyQvia and their previous treatment, how their work productivity and ...
What is the current status of trial NCT06538064?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-04-29. Estimated completion is 2027-08-17.
What conditions does trial NCT06538064 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).
What interventions are being tested in trial NCT06538064?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06538064?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06538064 being conducted?
This trial has 15 study locations across California, Connecticut, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI